Disclosed are pharmaceutical compositions for the treatment or prevention of chemokine mediated conditions, such as multiple sclerosis or related conditions, containing 3,4,5-trisubstituted aryl nitrones, and methods for the treatment or prevention of multiple sclerosis and related conditions. The 3,4,5-trisubstituted aryl nitrones have the formula: 1 where R.sup.1-R.sup.3 and Q are as defined in the specification, or the 3,4,5-trisubstituted aryl nitrones have the formula: 2 where R.sup.1-R.sup.3 and Q are as defined in the specification.